Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F61 injection for severe COVID-19
ChiCTR2300067655Phase 2Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of F61 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Ruijin Hospital. Primary endpoint: Proportion of subjects who became critically severe within 14 days after first follow-up. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
F61
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2300067655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300067655.